Metropolis Healthcare launches new test 'CoviRisk TBNK'; Stock gains 1%

The test is available in India for Rs4500 and the TAT is within 6 hours of receiving the sample.

July 22, 2021 10:07 IST | India Infoline News Service
Metropolis Healthcare Ltd, India’s leading diagnostic service provider, has announced the launch of a simple blood test that will be able to identify the risk status of a hospitalized COVID-19 patient.

CoviRisk – TBNK (IVD approved Flow Cytometry-based lymphocyte subset assay, that estimates T, B, and Natural Killer (NK) cells besides the CD4 and CD8 subpopulations of T-cells in peripheral blood) for cell- mediated response to SARS CoV2 test can assist clinicians to identify severity and prognosis, in triaging of hospitalized COVID-19 patients, and helps to determine if a patient might require IMV (Intubation with Mechanical Ventilation) and ICU facility.

The test is available in India for Rs4500 and the TAT is within 6 hours of receiving the sample.

In individuals with severe clinical courses, the disease often manifests in two waves. In the first, the patient has typical clinical symptoms of respiratory tract infection, and after 8–12 days, the second wave starts with sudden worsening of respiratory status.

Diffuse ground-glass opacities on CT, lymphopenia, elevated D-dimer levels, and prolonged prothrombin time are common laboratory abnormalities in these critically ill patients. Although documented in all ages, the mortality rate is particularly high among the elderly & those with pre-existing co-morbidities (such as diabetes, hypertension, and chronic lung disease). Increased levels of interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α) have been documented in severely infected individuals.

According to reports, every time there is a spike in COVID-19 cases, the number of beds in hospitals and especially the ICU beds fall short in almost all major cities despite all advance preparations. Especially the recent second wave has overwhelmed the healthcare system, leaving hospitals struggling to cope with the shortage of critical drugs, oxygen cylinders, and ICU beds.

Hence, the urgent need of the hour was to focus on enhancing patient care while prioritizing hospital resources.

Multiple studies and evidence suggest that Flow Cytometry data can be used to explore the role of T-Cell subtypes as a surrogate biomarker to risk, disease severity, and clinical outcomes for patients suffering from COVID-19. CoviRisk TBNK by Flowcytometry can be one of such biomarkers.

Speaking about the test launch, Ameera Shah, Promoter & Managing Director of Metropolis Healthcare Ltd. said, “We are glad to launch the CoviRisk TBNK test just in time before the 3rd wave. As no one is aware of the extent of uncertainties India could face, the need of the hour is early recognition of the right course of action for hospitalised COVID-19 patients which can help in making the right treatment choice for patients while prioritizing precious resources.”

Dr. Kirti Chadha, Group Head Medical Affairs at Metropolis Healthcare Ltd. said, “CD4 and CD8 T cells are important for triggering an immune response to bacterial and viral infections. CBC is carried out in patients with infections, while CBC can detect lymphopenia in blood, it cannot measure the specific lymphocyte populations that are impacting the normal immune response.

In COVID-19 patients, the CD4 and CD8 T cell counts typically decrease with increasing severity of the disease and can help assess the immune response of COVID-19 patients. CD3+ CD8+ T lymphocytes, CD16+ CD56+ NK cells, C1q as well as IL-6 may play critical roles in the inflammatory cytokine storm. The dysregulation of these immune parameters, along with bacterial coinfection are important causes of exacerbation of the patients’ condition and death.”

Dr. Sanjay Gohil, MD (Path) Consultant Pathologist Head of Dept. Haematology & Transplant Immunology (HLA) Metropolis Healthcare Ltd. said, “With the 3rd wave of the pandemic lurking around the corner, we wanted to add this new diagnostic test to help arm our healthcare warriors. This test could provide the much-needed assurance to the patients and will help reduce the stress on our healthcare infrastructure as well as medical professionals by helping them identify the level of risk and accordingly take the next steps.”

Metropolis Healthcare Ltd. has been at the forefront of COVID testing across the country from day one of the pandemic, right from COVID PCR tests to COVID monitoring profiles, COVID antibody tests, and various tests related to COVID associated illnesses such as mucormycosis. In its pursuit to offer the best possible tests for the citizens, the company has launched the first of its kind CoviRisk TBNK test in the country.

At around 10:07 AM, Metropolis Healthcare was trading at Rs2,836 apiece up by Rs26.45 or 0.94% on Sensex.

FREE Benefits Worth 5,000



Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity